Pfizer is advancing the development of a once-daily weight-loss pill, danuglipron, following promising pharmacokinetic and safety data from ongoing trials. This move comes after discontinuing a twice-daily version due to high rates of side effects like nausea and vomiting. The company will conduct dose optimization studies in 2024 to refine the preferred formulation for future registration-enabling studies. The new formulation aims to compete with existing injectable GLP-1 receptor agonists like Novo Nordisk’s Wegovy and Ozempic. Pfizer's scientific leadership expresses cautious optimism about the potential market impact. Pfizer’s shares rose following the announcement.